Top

CNS Drugs

Published in:

01-06-2006 | Review Article

Affective Disorders in Patients with HIV Infection

Impact of Antiretroviral Therapy

Author: Dr Gabriele Arendt

Published in: CNS Drugs | Issue 6/2006

Abstract

At the beginning of the AIDS pandemic, affective disorders (such as depressed mood) were seen in a considerable number of HIV-1-infected individuals. These disorders were a result of the poor physical condition of the patients, brain involvement by the virus (e.g. encephalopathy) or a reaction to disadvantageous living conditions (losing friends, jobs, etc.). In the era of highly active antiretroviral therapy (HAART), mental illness related to physical weakness is declining, as is the incidence of HIV-1-associated encephalopathy. However, depressed mood and fatigue caused by efavirenz (a standard component of HAART) is becoming increasingly important, particularly in individuals who are infected long-term with HIV-1. Whatever the cause of affective disorders, their presence has been shown to negatively influence adherence to HAART and HIV-1 disease progression.

Specialist knowledge of HIV-1 infection, and HAART and its psychiatric complications (particularly in subgroups of patients such as drug abusers and older people), is needed to care adequately for patients. Furthermore, prospective studies are needed to more fully differentiate between the various aetiologies of affective disorders seen in individuals living with HIV/AIDS and to determine their incidence and prevalence. Such information is important to ensure that affective disorders are recognised and adequately treated, which will in turn improve the efficacy of HAART.

Maj M, Janssen R, Starace F, et al. WHO Neuropsychiatric AIDS Study, cross-sectional phase I: study design and psychiatric findings. Arch Gen Psychiatry 1994 Jan; 51(1): 39–49PubMedCrossRef

Himelhoch S, Moore RD, Treisman G, et al. Does the presence of a current psychiatric disorder in AIDS patients affect the initiation of antiretroviral treatment and duration of therapy? J Acquir Immune Defic Syndr 2004 Dec; 37(4): 1457–63PubMedCrossRef

O’Mahoney SM, Myint AM, Steinbusch H, et al. Efavirenz induces depressive-like behaviour, increased stress response and changes in the immune response in rats. Neuroimmunomodulation 2005; 12(5): 293–8CrossRef

Barfod TS, Gerstoft J, Rodkjaer L, et al. Patients’ answers to simple questions about treatment satisfaction and adherence and depression are associated with failure of HAART: a cross-sectionalsurvey. AIDS Patient Care STDS 2005 May; 19(5): 317–25PubMedCrossRef

Trepanier LL, Rourke SB, Bayoumi AM, et al. The impact of neuropsychological impairment and depression on health related quality of life in HIV-infection. J Clin Exp Neuropsychol 2005 Jan; 27(1): 1–15PubMedCrossRef

Drebing CE, Van Gorp WG, Hinkin C, et al. Confounding factors in the measurement of depression in HIV. J Pers Assess 1994; 62: 68–83PubMedCrossRef

Rabkin J. Depression and HIV. Focus 2004 Oct; 19(10): 1–5PubMed

Atkinson JH, Grant I. Prevalence of psychiatric disorders among men infected with human immunodeficiency virus. Arch Gen Psychiatry 1988; 45: 859–64PubMedCrossRef

Kelly B, Raphael B, Judd F, et al. Psychiatric disorder in HIV infection. Aust N Z J Psychiatry 1998 Jun; 32(3): 441–53PubMedCrossRef

10.

Horwath E. Psychiatric and neuropsychiatric manifestations of HIV infection. J Int Assoc Physicians AIDS Care (Chic Ill) 2002 Nov; 1Suppl. 1: S1–15

11.

Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 2001 Aug; 58(8): 721–8PubMedCrossRef

12.

Robins LN, Regier DA, editors. Psychiatric disorders in America. New York: The Free Press, 1991

13.

Morrison M, Petitto J, Ten Have T, et al. Depressive and anxiety disorders in women with HIV infection. Am J Psychiatry 2002; 5: 789–96CrossRef

14.

Cruess DG, Douglas SD, Petitto JM, et al. Association of resolution of major depression with increased natural killer cell activity among HIV-seropositive women. Am J Psychiatry 2005 Nov; 162(11): 2125–30PubMedCrossRef

15.

Ickovics JR, Hamburger ME, Viahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA 2001 Mar 21; 285(11): 1466–74PubMedCrossRef

16.

Uldall KK, Palmer NB, Whetten K, et al. Adherence in people living with HIV/AIDS, mental illness, and chemical dependency: a review of the literature. AIDS Care 2004; 16Suppl. 1: S71–96PubMedCrossRef

17.

Kielan K, Kucharska-Pietura K, Warchala A, et al. The integration of the computer advisory system together with neuroimaging procedures, neurophysiological markers and psychological cognitive tests in order to obtain evidence based system for the physician treating affective disturbance. Wiad Lek 2004; 57 Suppl. 1: 158–62

18.

Griffin KW, Rabkin JG, Remien RH, et al. Disease severity, physical limitations and depression in HIV-infected men. J Psychosom Res 1998; 44: 219–27PubMedCrossRef

19.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. Washington, DC: American Psychiatric Association, 1994

20.

Bauer M, Pfennig A. Epidemiology of bipolar disorders. Epilepsia 2005; 46Suppl. 4: 8–13PubMedCrossRef

21.

Atkinson JH, Grant I. Mood disorder due to human immunodeficiency virus: yes, no, or maybe? Semin Clin Neuropsychiatry 1997; 2: 276–84PubMed

22.

Ellen SR, Judd FK, Mijch AM, et al. Secondary mania in patients with HIV infection. Aust N Z J Psychiatry 1999; 33: 353–60PubMedCrossRef

23.

Hutchinson G. HIV mania as a marker for clinical deterioration in AIDS. West Indian Med J 2005 Mar; 54(2): 149–51PubMedCrossRef

24.

Lyketsos CG, Schwartz J, Fishman M, et al. AIDS mania. J Neuropsychiatry Clin Neurosci 1997; 9(2): 277–99PubMed

25.

Lyketsos CG, Schwartz J, Fishman M, et al. AIDS mania. J Neuropsychiatry Clin Neurosci 1997; 9: 277–9PubMed

26.

Bauer LO, Ceballos NA, Shanley JD, et al. Sensorimotor dysfunction in HIV/AIDS: effects of antiretroviral treatment and comorbid psychiatric disorders. AIDS 2005; 19(5): 495–502PubMedCrossRef

27.

Hriso E, Kuhn T, Masdeu JC, et al. Extrapyramidal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathy. Am J Psychiatry 1991; 148: 1558–61PubMed

28.

Thompson A, Silverman B, Dzeng L, et al. Psychotropic medications and HIV. Clin Infect Dis 2006 May: 42(9): 1305–10. Epub 2006 Mar 27PubMedCrossRef

29.

Taylor MJ, Goodwin GM. Long-term prophylaxis in bipolar disorder. CNS Drugs 2006; 20(4): 303–10PubMedCrossRef

30.

Fell M, Newman S, Herns M, et al. Mood and psychiatric disturbance in HIV and AIDS: changes over time. Br J Psychiatry 1993; 162: 604–10PubMedCrossRef

31.

Baldeweg T, Gruzelier JH. Alpha EEG activity and subcortical pathology in HIV infection. Int J Psychophysiol 1997; 26(1–3): 431–42PubMedCrossRef

32.

Stout JC, Ellis RJ, Jernigan TL, et al. Progressive cerebral volume loss in human immunodeficiency virus infection: a longitudinal volumetric magnetic resonance imaging study. HIV Neurobehavioral Research Center Group. Arch Neurol 1998 Feb; 55(2): 161–8

33.

Waldrop-Valverde D, Ownby RL, Kumar M. Influence of depression and HIV serostatus on the neuropsychological performance of injecting drug users. Psychiatry Clin Neurosci 2005; 59(4): 372–8PubMedCrossRef

34.

Kessler R, McGonagle K, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 8–19PubMedCrossRef

35.

Kessler RC, Berglund P, Demier O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003 Jun; 289(23): 3095–105PubMedCrossRef

36.

Hasin DS, Goodwin RD, Stinson FS, et al. Epidemiology of major depressive disorder: results from the National Epidemiology Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry 2005 Oct; 62(10): 1097–106PubMedCrossRef

37.

Evans DL, Mason K, Bauer R, et al. Neuropsychiatric manifestations of HIV-1 infection and AIDS. In: Charney D, Coyle J, Davis K, et al., editors. Psychopharmacology: the fifth generation of progress. New York: Raven Press, 2002: 1281–300

38.

Rabkin JG, McElhiney M, Ferrando S, et al. Psychopathology in male and female HIV-positive and negative injecting drug users: longitudinal course over 3 years. AIDS 1997; 11: 507–15PubMedCrossRef

39.

Justice AC, McGinnis KA, Atkinson JH, et al. Psychiatric and neurocognitive disorders among HIV-positive and negative veterans in care: Veterans Aging Cohort Five-Site Study. AIDS 2004; 18Suppl. 1: S49–59PubMed

40.

Rabkin JG, McElhiney MC, Ferrando SJ. Mood and substance use disorders in older adults with HIV/AIDS: methodological issues and preliminary evidence. AIDS 2004; 18Suppl. 1: S43–8PubMed

41.

Cherner M, Ellis RJ, Lazzaretto D, et al. Effects of HIV-infection and aging on neurobehavioral functioning: preliminary findings. AIDS 2004; 18Suppl. 1: S27–34PubMed

42.

Lyketsos CG, Hoover DR, Guccione M, et al. Changes in depressive symptoms as AIDS develops. The Multicenter Aids Cohort Study. Am J Psychiatry 1996; 153: 1430–7

43.

Atkinson JH, Grant I. Natural history of neuropsychiatric manifestations of HIV disaese. Psychiatr Clin North Am 1994; 17: 17–33PubMed

44.

Gielen AC, McDonnell KA, O’Campo PJ, et al. Suicide risk and mental health indicators: do they differ by abuse and HIV status? Womens Health Issues 2005 Mar–Apr; 15(2): 89–95PubMedCrossRef

45.

Blaney NT, Fernandez MI, Ethier KA, et al. Psychosocial and behavioral correlates of depression among HIV-infected pregnant women. AIDS Patient Care STDS 2004; 18(7): 405–15PubMedCrossRef

46.

Kwalombota M. The effect of pregnancy in HIV-infected woman. AIDS Care 2002; 14(3): 431–3PubMedCrossRef

47.

Moore J, Schuman P, Schoenbaum E, et al. Severe adverse life events and depressive symptoms among women with or at risk for HIV infection in four cities in the United States of America. AIDS 1999; 13: 2459–68PubMedCrossRef

48.

Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry 2001; 158: 725–30PubMedCrossRef

49.

Maj M. Depressive syndromes and symptoms in subjects with human immunodeficiency virus (HIV) infection. Br J Psychiatry Suppl 1996; 30: 117–22PubMed

50.

Weiser SD, Wolfe WR, Bangsberg DR. The HIV epidemic among individuals with mental illness in the United States. Curr HIV/AIDS Rep 2004; 1(4): 186–92PubMedCrossRef

51.

Snider W, Simpson D, Nielson S, et al. Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients. Ann Neurol 1983; 14: 403–18PubMedCrossRef

52.

Arendt G, Hefter H, Elsing C, et al. Motor dysfunction in HIV-infected patients without clinically detectable central-nervous deficit. J Neurol 1990; 237(6): 362–8PubMedCrossRef

53.

Giesen HJ, Antke C, Hefter H, et al. Potential time course of HIV-1-associated minor motor deficits: electrophysiological and PET findings. Arch Neurol 2000; 57(11): 1601–7CrossRef

54.

Giesen HJ, Wittsack HJ, Wenserski F, et al. Basal ganglia metabolite abnormalities in HIV-1-associated minor motor deficits. Arch Neurol 2001; 58: 1281–6CrossRef

55.

Giesen HJ, Bäcker R, Hefter H, et al. Depression does not influence basal ganglia-mediated psychomotor speed in HIV-1 infection. J Neuropsychiatry Clin Neurosci 2001; 13(1): 88–94CrossRef

56.

Millikin CP, Trepanier LL, Rourke SB. Verbal fluency component analysis in adults with HIV/AIDS. J Clin Exp Neuropsychol 2004; 26(7): 933–42PubMedCrossRef

57.

Farinpour R, Miller EN, Satz P, et al. Psychosocial risk factors of HIV morbidity and mortality: findings from the Multicenter AIDS Cohort Study (MACS). J Clin Exp Neuropsychol 2003; 25(5): 654–70PubMedCrossRef

58.

Evans DL, Ten Have TR, Douglas SD, et al. Association of depression with viral load, CD8T lymphocytes, and natural killer cells in women with HIV infection. Am J Psychiatry 2002; 159: 1752–9PubMedCrossRef

59.

Ickovics JR, Hamburger ME, Vlahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women. JAMA 2001; 285: 1466–74PubMedCrossRef

60.

Cook JA, Cohen MH, Burke J, et al. Effects of depressive symptoms and mental health quality of life on use of highly active antiretroviral therapy among HIV-seropositive women. J Acquir Immune Defic Syndr 2002; 30(4): 401–9PubMed

61.

Jia H, Uphold CR, Wu S, et al. Predictors of changes in health-related quality of life among men with HIV infection in the HAART era. AIDS Patient Care STDS 2005; 19(6): 395–405PubMedCrossRef

62.

Williams CT, Latkin CA. The role of depressive symptoms in predicting sex with multiple and high-risk partners. J Acquir Immune Defic Syndr 2005; 38(1): 69–73PubMedCrossRef

63.

Gonzalez JS, Penedo FJ, Antoni MH, et al. Social support, positive states of mind, and HIV treatment adherence in men and women living with HIV/AIDS. Health Psychol 2004; 23(4): 413–8PubMedCrossRef

64.

Kopnisky KL, Stoff DM, Rausch DM. Workshop report: the effects of psychological variables on the progression of HIV-1 disease. Brain Behav Immun 2004; 18(3): 246–61PubMedCrossRef

65.

Paul RH, Brickman AM, Navia B, et al. Apathy is associated with volume of the nucleus accumbens in patients infected with HIV. J Neuropsychiatry Clin Neurosci 2005 Spring; 17(2): 167–71PubMedCrossRef

66.

Paul R, Flanigan TP, Tashima K, et al. Apathy correlates with cognitive function but not CD4 status in patients with human immunodeficiency virus. J Neuropsychiatry Clin Neurosci 2005; 17(1): 114–8PubMedCrossRef

67.

Tate D, Paul RH, Flanigan TP, et al. The impact of apathy and depression on quality of life in patients infected with HIV. AIDS Patient Care STDS 2003; 17(3): 115–20PubMedCrossRef

68.

Perez-Molina JA. Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients. HIV Clin Trials 2002 Jul–Aug; 3(4): 279–86PubMedCrossRef

69.

Lochet P, Peyière H, Lotthe A, et al. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med 2003; 4(1): 62–6PubMedCrossRef

70.

Spire B, Carried P, Garzot MA, et al. Factors associated with efavirenz discontinuation in a large community-based sample of patients. AIDS Care 2004; 16(5): 558–64PubMedCrossRef

71.

Miro O, Lopez S, Cardellach F, et al. Mitochondrial studies in HAART-related lipodystrophy: from experimental hypothesis to clinical findings. Antivir Ther 2005; 10Suppl. 2: M73–81PubMed

72.

Echavez M, Horstman W. Relationship between lipoatrophy and quality of life. AIDS Read 2005; 15(7): 369–75PubMed

73.

Burgoyne R, Collins E, Wagner C, et al. The relationship between lipodystrophy-associated body changes and measures of quality of life and mental health for HIV-positive adults. Qual Life Res 2005; 14(4): 981–90PubMedCrossRef

74.

Nicholas PK, Kirksey KM, Corless IB, et al. Lipodystrophy and quality of life in HIV: symptom management issues. Appl Nurs Res 2005; 18(1): 55–8PubMedCrossRef

75.

Cove J, Petrak J. Factors associated with sexual problems in HIV-positive gay men. Int J STD AIDS 2004; 15(11): 732–6PubMedCrossRef

76.

Collazos J, Martinez E, Mayo J, et al. Sexual dysfunction in HIV-infected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002 Nov; 31(3): 322–6PubMedCrossRef

77.

Henderson M, Safa F, Easterbrook P, et al. Fatigue among HIV-infected patients in the era of highly active antiretroviral therapy. HIV Med 2005; 6(5): 347–52PubMedCrossRef

78.

Voss JG. Predictors and correlates of fatigue in HIV/AIDS. J Pain Symptom Manage 2005; 29(2): 173–84PubMedCrossRef

79.

Millikin CP, Rourke SB, Halman MH, et al. Fatigue in HIV/ AIDS is associated with depression and subjective neurocognitive complaints but not neuropsychological functioning. J Clin Exp Neuropsychol 2003; 25(2): 210–5CrossRef

80.

Phillips KD, Sowell RL, Rojas M, et al. Physiological and psychological correlates of fatigue in HIV disease. Biol Res Nurs 2004 Jul; 6(1): 59–7PubMedCrossRef

81.

Lee KA, Portillo CJ, Miramontes H. The influence of sleep and activity pattern on fatigue in women with HIV/AIDS. J Assoc Nurses AIDS Care 2001; 12 Suppl.: 19–27PubMed

82.

Rabkin JG, McElhiney MC, Rabkin R, et al. Modafinil treatment for fatigue in HIV+ patients: a pilot study. J Clin Psychiatry 2004; 65(12): 1688–95PubMedCrossRef

83.

Rabkin JG, Wagner GJ, McElhiney MC, et al. Testosteroneversus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial. J Clin Psychopharmacol 2004; 24(4): 379–85PubMedCrossRef

84.

Braitstein P, Montessori V, Chan K, et al. Quality of life, depression and fatigue among persons co-infected with HIV and hepatitis C: outcomes from a population-based cohort. AIDS Care 2005; 17(4): 505–15PubMedCrossRef

85.

Kalyoncu OA, Tan D, Mirsal H. Major depressive disorder with psychotic features induced by interferon-alpha treatment for hepatitis C in a polydrug abuser. J Psychopharmacol 2005; 19(1): 102–5PubMedCrossRef

86.

Taylor LE, Gholam PM, Schwartzapfel B, et al. Hepatitis C treatment in an HIV-HCV-coinfected patient with drug addiction and psychiatric illness: a case report. AIDS Read 2005 Nov; 15(11): 629–31, 634-6, 638PubMed

87.

Laguno M, Blanch J, Murillas J. Depressive symptoms after initiation of interferon-alpha therapy in human immunodeficiency virus-infected patients with chronic hepatitis C. Antivir Ther 2004; 9(6): 905–9PubMed

88.

Ryan EL, Morgello S, Isaacs K, et al. Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology 2004; 62(6): 957–62PubMedCrossRef

89.

Sperner-Unterweger B. Immunological aetiology of major psychiatric disorders: evidence and therapeutic implications. Drugs 2005; 65(11): 1493–520PubMedCrossRef

90.

Tsao JC, Dobalian A, Naliboff BD. Panic disorder and pain in a national sample of persons living with HIV. Pain 2004; 109(1–2): 172–80PubMedCrossRef

91.

Reynolds NR, Testa MA, Marc LG. Factors influencing medication adherence beliefs and self-efficacy in persons naive to antiretroviral therapy: a multicenter, cross-sectional study. AIDS Behav 2004; 8(2): 141–50PubMedCrossRef

92.

Kleeberger CA, Buechner J, Pallela F, et al. Changes in adherence to highly active antiretroviral therapy medications in the Multicenter AIDS Cohort Study. AIDS 2004; 18(4): 683–8PubMedCrossRef

93.

Li X, Margolick JB, Conover CS, et al. Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2005; 38(3): 320–8PubMed

94.

Murphy DA, Beizer M, Durako SJ, et al. Longitudinal antiretroviral adherence among adolescents infected with human immunodeficiency virus. Arch Pediatr Adolesc Med 2005; 159(8): 764–70PubMedCrossRef

95.

Ammassari A, Antinori A, Aloisi MS. Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics 2004; 45(5): 394–402PubMedCrossRef

96.

Starace F, Bartoli L, Aloisi MS, et al. Cognitive and affective disorders associated to HIV infection in the HAART era: findings from the NeuroICONA study. Cognitive impairment and depression in HIV/AIDS. The NeuroICONA study. Acta Psychiatr Scand 2002; 106(1): 20–6

97.

Williams P, Narciso L, Browne G, et al. The prevalence, correlates, and costs of depression in people living with HIV/AIDS in Ontario: implications for service directions. AIDS Educ Prev 2005; 17(2): 119–30PubMedCrossRef

98.

Sambamoorthi U, Walkup J, Olfson M, et al. Antidepressant treatment and health services utilization among HIV-infected medicaid patients diagnosed with depression. J Gen Intern Med 2000 May; 15(5): 311–20PubMedCrossRef

99.

Phillips KD, Moneyham L, Murdaugh C, et al. Sleep disturbance and depression as barriers to adherence. Clin Nurs Res 2005; 14(3): 273–93PubMedCrossRef

100.

Bachanas PJ, Morris MK, Lewis-Gess JK, et al. Psychological adjustment, substance use, HIV knowledge, and risky sexual behavior in at-risk minority females: developmental differences during adolescence. J Pediatr Psychol 2002; 27(4): 373–84PubMedCrossRef

101.

Yun LW, Maravi M, Kobayashi JS, et al. Antidepressant treatment improves adherence to antiretroviral therapy among depressed HIV-infected patients. J Acquir Immune Defic Syndr 2005 Apr; 38(4): 432–8PubMedCrossRef

102.

Zisook S, Peterkin J, Goggin KJ, et al. Treatment of major depression in HIV-seropositive men. HIV Neurobehavioral Research Center Group. J Clin Psychiatry 1998; 59: 217–24

103.

Elliott AJ, Russo J, Bergam K, et al. Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: an open trial of nefazodone. J Clin Psychiatry 1999; 60: 226–31PubMedCrossRef

104.

Caballero J, Nahata MC. Use of selective serotonin-reuptake inhibitors in the treatment of depression in adults with HIV. Ann Pharmacother 2005; 39(1): 141–5PubMed

105.

Pieper AA, Treisman GJ. Drug treatment of depression in HIV-positive patients: safety considerations. Drug Saf 2005; 28(9): 753–62PubMedCrossRef

106.

Cheer SM, Goa KL. Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness. Drugs 2001; 61(1): 81–110PubMedCrossRef

107.

Caballero J, Nahata MC. Use of selective serotonin-reuptake inhibitors in the treatment of depression in adults with HIV. Ann Pharmacother 2005; 39(1): 141–5. Epub 2004 Nov 23PubMed

108.

DeSilva KE, LeFlore DB, Marston BJ, et al. Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine. AIDS 2001; 15(10): 1281–5PubMedCrossRef

109.

Rogers G, Curry M, Oddy J, et al. Depressive disorders and unprotected casual anal sex among Australian homosexually active men in primary care. HIV Med 2003; 4(3): 271–5PubMedCrossRef

110.

Alciati A, Starace F, Scaramelli B, et al. Has there been a decrease in the prevalence of mood disorders in HIV-seropositive individuals since the introduction of combination therapy? Eur Psychiatry 2001; 16(8): 491–6PubMedCrossRef

111.

Rabkin JG, Ferrando SJ, Lin SH, et al. Psychological effects of HAART: a 2-year study. Psychosom Med 2000; 62(3): 413–22PubMed

112.

Safren SA, Radomsky AS, Otto MW, et al. Predictors of psychological well-being in a diverse sample of HIV-positive patients receiving highly active antiretroviral therapy. Psychosomatics 2002; 43(6): 478–85PubMedCrossRef

113.

Siegel K, Karus D, Dean L. Psychosocial characteristics of New York City HIV-infected women before and after the advent of HAART. Am J Public Health 2004; 94(7): 1127–32PubMedCrossRef

Title: Affective Disorders in Patients with HIV Infection
Impact of Antiretroviral Therapy
Author: Dr Gabriele Arendt
Publication date: 01-06-2006
Publisher: Springer International Publishing
Published in: CNS Drugs / Issue 6/2006
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200620060-00005

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Affective Disorders in Patients with HIV Infection

Impact of Antiretroviral Therapy

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2006

Cognitive Deficits and Psychosis in Parkinson’s Disease

Antioxidants in Multiple Sclerosis

The Mitochondrial Myopathy Encephalopathy, Lactic Acidosis with Stroke-Like Episodes (MELAS) Syndrome

Long-Term Pharmacotherapy for Post-Traumatic Stress Disorder

Spotlight on Remifentanil: its Analgesic and Sedative Use in the Intensive Care Unit